Highlight from “The TPP’s final intellectual property (IP) chapter and access to medicines”

Despite resistance by the majority of TPP countries to the US pharmaceutical industry agenda throughout the negotiations, many provisions remain in the final text that will reduce access to affordable medicines, particularly in developing countries. These problems will be exacerbated by limited, short and inflexible transition periods for developing countries to implement the obligations…

Loading data